title: The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development.
abstract: Successful completion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, reported in this issue of Cancer Discovery, is an important advance in the effort to improve clinical trial approaches to the simultaneous development of new therapeutics with matching diagnostic tests so that patients most likely to benefit from these therapies can be identified.
authors.affiliation: Merck Research Laboratories, North Wales, Pennsylvania 19454, USA. eric_rubin@merck.com
authors.forename: Eric H
authors.initials: EH
authors.lastname: Rubin
authors.forename: Keaven M
authors.initials: KM
authors.lastname: Anderson
authors.forename: Christine K
authors.initials: CK
authors.lastname: Gause
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor